At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
Exenatide +1 moredrug
Likely dose
Exenatide 5 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Insulin Glargine and Exenatide: A Randomized Clinical Trial With Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis
In Brief
A clinical study evaluating Exenatide and Insulin Glargine for Type 2 Diabetes. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The primary purpose of this study is to compare the effect on 24-hour blood glucose patterns, HbA1c, and weight management when adding insulin glargine, or exenatide, or a combination of insulin glargine and exenatide to metformin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsInternational Diabetes Center at Park Nicollet, Sanofi
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2010
Enrollment StartApr 2010
Primary CompletionMay 2013
TodayJul 2026
First PostedMar 18, 2010
Enrollment StartApr 1, 2010
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 16.3 years ago
Interventions
Exenatidedrug
5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
Insulin Glarginedrug
.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results